Our laboratory is primarily interested in the molecular neuropathology and therapeutic strategies for Alzheimer´s disease (AD). AD is the most common age-related neurodegenerative disorder afflicting more than 10% of the population over 65 years of age. In 2000, the number of prevalent AD cases in the entire European region was 4.7 million. With increasing life expectancy and age being the major risk factor for AD, projections indicate that these numbers will surge to about 11.2 million cases in the year 2050. This trend constitutes a dramatic challenge for the public health care system, and effective means of treatment or prevention of AD are urgently needed.